Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.

Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Inhibition of death receptor signals by cellular FLIP

Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,548

A cell culture model for T lymphocyte clonal anergy

Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505

Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465

CD4+CD25+ Immunoregulatory T Cells

McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395

Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

The Immunobiology of Cancer Immunosurveillance and Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,192

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Zhang, Y., & Zhang, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,906

Natural Innate and Adaptive Immunity to Cancer

Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,225

Regulatory T cells, tumour immunity and immunotherapy

Zou, W. (2006) · Nature reviews. Immunology · doi:10.1038/nri1806 · Cited by 2,135

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688

Inhibitory B7-family molecules in the tumour microenvironment

Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,347

From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,342

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth

Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175

Inflammation, a Key Event in Cancer Development

Lu, H., Ouyang, W., & Huang, C. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0261 · Cited by 1,049

Targeting neoantigens to augment antitumour immunity

Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997

Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity

Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 919

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852

Adoptive immunotherapy for cancer: building on success

Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature reviews. Immunology · doi:10.1038/nri1842 · Cited by 852

Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression

Serafini, P., Borrello, I., & Bronte, V. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 775

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748

Adoptive-cell-transfer therapy for the treatment of patients with cancer

Dudley, M. E., & Rosenberg, S. A. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1167 · Cited by 653

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

Landsberg, J., Sirokay, J. D., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 652

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach

Zeisberger, S. M., Odermatt, B., Marty, C., Zehnder-Fjällman, A. H. M., Ballmer‐Hofer, K., & Schwendener, R. A. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603240 · Cited by 622

Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape

Mohme, M., Riethdorf, S., & Pantel, K. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 616

Therapeutic Cancer Vaccines

Guo, C., Manjili, M. H., Subjeck, J. R., Sarkar, D., Fisher, P. B., & Wang, X. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 621

Immunological landscape and immunotherapy of hepatocellular carcinoma

Prìeto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 573

CD4 and CD8 T lymphocyte interplay in controlling tumor growth

Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 566

Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance

Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S. R., Pratt, B. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 549

Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

Vago, L., Perna, S. K., Zanussi, M., Mazzi, B. A., Barlassina, C., Stanghellini, M. T. L., Perrelli, N. F., Cosentino, C., Torri, F., Angius, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0811036 · Cited by 532

Expression of tumour-specific antigens underlies cancer immunoediting

DuPage, M. J. P., Mazumdar, C., Schmidt, L., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529

CD8 + T‐cell memory in tumor immunology and immunotherapy

Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511

Impact of Stress on Cancer Metastasis

Moreno‐Smith, M., Lutgendorf, S. K., & Sood, A. K. (2010) · Future Oncology · doi:10.2217/fon.10.142 · Cited by 522

Clonal Origin and Evolution of a Transmissible Cancer

Murgia, C., Pritchard, J. K., Kim, S. Y., Fassati, A., & Weiss, R. A. (2006) · Cell · doi:10.1016/j.cell.2006.05.051 · Cited by 489

Immunotherapy: Reshape the Tumor Immune Microenvironment

Bingzhe, L. V., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 500

Acquired resistance to immunotherapy and future challenges

Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.2 · Cited by 470

Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

Rosenberg, S. A., Sherry, R. M., Morton, K. E., Sharfman, W., Yang, J. C., Topalian, S. L., Royal, R. E., Kammula, U. S., Restifo, N. P., Hughes, M. S., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6169 · Cited by 460

Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy

Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 457

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

Willimsky, G., & Blankenstein, T. J. F. (2005) · Nature · doi:10.1038/nature03954 · Cited by 439

The determinants of tumour immunogenicity

Blankenstein, T. J. F., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3246 · Cited by 454

New insights into the role of EMT in tumor immune escape

Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

Rubio, V., Stuge, T. B., Singh, N. S., Betts, M. R., Weber, J. S., Roederer, M., & Lee, P. P. (2003) · Nature Medicine · doi:10.1038/nm942 · Cited by 400

Alterations of immune response of non-small cell lung cancer with Azacytidine

Wrangle, J. M., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F. P., Criekinge, W. V., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 389

Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma

Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P. J., Mottram, P. J., Curiel, T. J., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 409

Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion

Ginderachter, J. A. V., Movahedi, K., Ghassabeh, G. H., Meerschaut, S., Beschin, A., Raes, G., & BAETSELIER, P. D. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.06.002 · Cited by 372

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367

Prospects for gene-engineered T cell immunotherapy for solid cancers

Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 372

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

Muranski, P. J., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R. W., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

Tamborero, D., Rubio-Pérez, C., Muiños, F., Sabarinathan, R., Piulats, J. M., Muntasell, A., Dienstmann, R., López-Bigas, N., & González-Pérez, A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3509 · Cited by 356

Prospects of RNA interference therapy for cancer

Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T. ‐. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352

The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy

Galili, U. (2005) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2005.01366.x · Cited by 335

CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours

Kruse, B., Buzzai, A. C., Shridhar, N., Braun, A. D., Gellert, S., Knauth, K., Poźniak, J., Peters, J., Dittmann, P., Mengoni, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06199-x · Cited by 353

Natural killer cells in human health and disease

Orange, J. S., & Ballas, Z. K. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.10.011 · Cited by 320

Dual role of macrophages in tumor growth and angiogenesis

Lamagna, C., Aurrand‐Lions, M., & Imhof, B. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105656 · Cited by 318

Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence

Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 323

Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells

Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299

Accelerated tumor growth in mice deficient in DNAM-1 receptor

Iguchi‐Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara‐Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 289

Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

Bollard, C. M., Gottschalk, S. M., Leen, A. M., Weiss, H. L., Straathof, K. C. M., Carrum, G., Khalil, M., Wu, M., Huls, M. H., Chang, C.-C., et al. (2007) · Blood · doi:10.1182/blood-2007-05-091280 · Cited by 278

Role of infiltrated leucocytes in tumour growth and spread

Lin, E. Y., & Pollard, J. W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601705 · Cited by 275

B7-H1 pathway and its role in the evasion of tumor immunity

Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 280

The impact of mitotic errors on cell proliferation and tumorigenesisPreprint

Levine, M. S., & Holland, A. J. (2018) · Genes & Development · doi:10.1101/gad.314351.118 · Cited by 274

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275

HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients

de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Natanov, R., Putter, H., Smit, V. T. H. B. M., Liefers, G., van den Elsen, P. J., van de Velde, C. J. �., & Kuppen, P. J. K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002629 · Cited by 268

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

Woll, P. S., Grzywacz, B. J., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 272

Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses

Zerbini, A., Pilli, M., Penna, A., Pelosi, G., Schianchi, C., Molinari, A., Schivazappa, S., Zibera, C., Fagnoni, F. F., Ferrari, C. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2244 · Cited by 267

Bystander elimination of antigen loss variants in established tumors

Spiotto, M. T., Rowley, D. A., & Schreiber, H. W. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260

Evolutionary biology of cancer

Crespi, B. J., & Summers, K. (2005) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2005.07.007 · Cited by 262

Eradication of established tumors in mice by a combination antibody-based therapy

Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita∥, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0224-x · Cited by 263

Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential

Lu, Y. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.009 · Cited by 256

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 261

The circadian clock in cancer development and therapy

Fu, L., & Kettner, N. M. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-396971-2.00009-9 · Cited by 251

Natural and Induced T Regulatory Cells in Cancer

Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 262

Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression

DuPage, M. J. P., Cheung, A. F., Mazumdar, C., Winslow, M. M., Bronson, R. T., Schmidt, L., Crowley, D. G., Chen, J., & Jacks, T. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.011 · Cited by 244

Host Factors and Cancer Progression: Biobehavioral Signaling Pathways and Interventions

Lutgendorf, S. K., Sood, A. K., & Antoni, M. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9357 · Cited by 249

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer

Anagnostou, V., & Brahmer, J. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1187 · Cited by 239

High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

Germeau, C., Ma, W., Schiavetti, F., Lurquin, C., Henry, E., Vigneron, N., Brasseur, F., Lethé, B., Plaen, E. D., Velu, T. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041379 · Cited by 232

Adoptive immunotherapy of cancer using CD4+ T cells

Muranski, P. J., & Restifo, N. P. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.004 · Cited by 230

Relapse after allogeneic stem cell transplantation

Barrett, A. J., & Battiwalla, M. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.32 · Cited by 218

Biobehavioral Factors and Cancer Progression

Lutgendorf, S. K., & Sood, A. K. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318235be76 · Cited by 213

How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Haabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F. H., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembić, Z., Corthay, A., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00174 · Cited by 208

Tumors as elusive targets of T-cell-based active immunotherapy

Marincola, F. M., Wang, E., Herlyn, M., Seliger, B., & Ferrone, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00116-9 · Cited by 201

Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis

Chiba, T., Ohtani, H., Mizoi, T., Naito, Y., Sato, E., Nagura, H., Ohuchi, A., Ohuchi, K., Shiiba, K., Kurokawa, Y., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602201 · Cited by 205

Acquired and intrinsic resistance in cancer immunotherapy

Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

Kruschinski, A., Moosmann, A., Poschke, I. C., Norell, H., Chmielewski, M. M., Seliger, B., Kiessling, R. W., Blankenstein, T. J. F., Abken, H., & Charo, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804788105 · Cited by 200

Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape

Salazar‐Onfray, F., López, M. N., & Mendoza‐Naranjo, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.015 · Cited by 216

Part I: Vaccines for solid tumours

D, S. M. M., Mandruzzato, S., Bronte, V., Lise, M., & Nitti, D. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01610-9 · Cited by 194

Roles of the immune system in skin cancer

Rangwala, S., & Tsai, K. Y. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10507.x · Cited by 191

High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway

Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Fujiwara, H., Masuzaki, H., Katabuchi, H., Kawakami, Y., Okamoto, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2725 · Cited by 189

Biobehavioral approaches to cancer progression and survival: Mechanisms and interventions.

Lutgendorf, S. K., & Andersen, B. L. (2015) · American Psychologist · doi:10.1037/a0035730 · Cited by 191

Interplay between DNA repair and inflammation, and the link to cancer

Kidane, D., Chae, W. J., Czochor, J. R., Eckert, K. A., Glazer, P. M., Bothwell, A. L. M., & Sweasy, J. B. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.875514 · Cited by 191

Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts

Bhattacharyya, S., Hossain, D. M. S., Mohanty, S., Sen, G. S., Chattopadhyay, S., Banerjee, S., Chakraborty, J., Das, K., Sarkar, D. K., Das, T., et al. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.11 · Cited by 189

Targeting death-inducing receptors in cancer therapy

Takeda, K., Stagg, J., Yagita∥, H., Okumura, K., & Smyth, M. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210374 · Cited by 187

Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy

Corbin, K. S., Hellmän, S., & Weichselbaum, R. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9651 · Cited by 185

Human Leukocyte Antigen and Antigen Processing Machinery Component Defects in Astrocytic Tumors

Facoetti, A., Nano, R., Zelini, P., Morbini, P., Benericetti, E., Ceroni, M., Campoli, M. R., & Ferrone, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2588 · Cited by 184

Targeting microRNAs as key modulators of tumor immune response

Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Călin, G. A., & Santarpia, L. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0375-2 · Cited by 184

Michor F: A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability

Iwami, S., Haeno, H., & Franziska Michor, A. (2016)

A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

Iwami, S., Haeno, H., & Michor, F. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002370 · Cited by 14

Immunotherapy and immunoselection ? tumour escape as the final hurdle

Pawelec, G. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.02.091 · Cited by 30

Strategies for tumor immune escape

Piemonti, L., Zerbi, A., & Carlo, V. D. (2003) · Drugs of today · doi:10.1358/dot.2003.39.9.799478 · Cited by 8

Abstract 4034: Immunotherapy generates selective pressure to create an escape tumor with increased susceptibility to treatment with T cell based therapies

Pan, J. H., Vodnala, S. K., Eil, R. L., Yu, Z., Gartner, J. J., Clever, D. C., Roychoudhuri, R., Patel, S. J., Klebanoff, C. A., Sukumar, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4034